ArticleLaboratory investigation; a journal of technical methods and pathology2018

ARHGEF39 promotes tumor progression via activation of Rac1/P38 MAPK/ATF2 signaling and predicts poor prognosis in non-small cell lung cancer patients.

Haijing Zhou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.